NewsSource: EClinCloud

Focusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC Practices

3 min readEClinCloud Editorial Team
SAPA-China 2026 CNS Forum on-site photo 1

By EClinCloud. Originally published on the "EClinCloud" WeChat Official Account on November 2, 2026.

On October 30, the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference was held in Suzhou. Zheng Liangyan, Medical Director at EClinCloud, delivered a keynote presentation titled "Pain Points and Solutions for Endpoint Assessment in Central Nervous System Disease Clinical Research," providing an in-depth discussion of key challenges, regulatory requirements, and practical implementation in CNS endpoint assessment, which drew attention and positive feedback from the audience.

SAPA-China 2026 CNS Forum on-site photo 1

SAPA-China 2026 CNS Forum on-site photo 2

SAPA-China 2026 CNS Forum on-site photo 3

01 Addressing Challenges in CNS Endpoint Assessment

Conditions such as Alzheimer's disease and Parkinson's disease are characterized by a long disease course, slow progression, and complex clinical manifestations; drug efficacy often requires comprehensive evaluation across multiple dimensions, including cognition, motor function, activities of daily living, and imaging.

Accordingly, accurately capturing clinical changes in patients and reducing subjective variability during assessment have become important factors affecting the quality of CNS clinical studies.

Drawing on the characteristics of CNS clinical research, the presentation noted that traditional assessment methods face three main challenges:

  • Clinical scales rely heavily on rater experience, and fluctuations in patient status can also introduce scoring variability;
  • Multicenter imaging acquisition standards are inconsistent and lack centralized quality control spanning both acquisition and reading;
  • CNS studies typically require long-term follow-up, and factors such as frequent hospital visits for elderly patients and the complexity of paper-based scales can easily increase patient burden and affect compliance and data integrity.

These challenges are interconnected and ultimately point to the question of how to establish a more standardized, objective, and sustainable endpoint assessment system.

02 Safeguarding Reliability with eCOA and IRC

To address these issues, the presentation focused on approaches to applying eCOA and IRC.

Through electronic scales, standardized rater training, automated scoring, and logic checks, eCOA reduces manual operations and variability during assessment, while lowering barriers to patient participation through BYOD, customized devices, and remote data capture. IRC improves the consistency and comparability of multicenter imaging data through unified imaging acquisition standards, centralized imaging quality control, independent blinded reading, and adjudication mechanisms.

Together, the two improve the reliability of endpoint assessment from different dimensions and have been applied in EClinCloud's actual projects:

In studies of conditions such as Alzheimer's disease and post-stroke cognitive impairment, EClinCloud has supported the standardized administration of complex scales and improved patient compliance through electronic scales, rater training, customized rating devices, and central quality control;

In an Alzheimer's disease study covering 1000+ patients, EClinCloud further integrated eCOA and IRC solutions, providing multidimensional endpoint data support for the study through electronic scales and independent imaging assessment.

From practical study experience, endpoint assessment quality cannot be achieved by relying on a single tool alone; rather, it requires combining standardized processes, specialized assessment capabilities, and digital technologies across every stage of study execution.

Looking ahead, with advances in AI technologies, wearable devices, and remote data capture, the integration of clinical outcome data and imaging data will offer greater possibilities for evaluating the efficacy of CNS drugs. EClinCloud will continue to deepen its focus on the CNS field, centering on core capabilities such as eCOA and IRC to help improve endpoint assessment quality in clinical research.

About EClinCloud

EClinCloud is a leading AI company in the clinical research industry. Powered by AI, it builds an integrated intelligent clinical cloud platform and endpoint assessment technologies, providing global pharmaceutical companies and research institutions with technology products including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as scale management, linguistic validation, rater training, and data quality analysis services to deliver efficient, precise digital solutions. Leveraging AI predictive models and an intelligent data platform, EClinCloud dynamically evaluates and helps improve drug clinical trial success rates, helping shorten drug and device development cycles for the benefit of patients.

Footer image from the original EClinCloud article


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoveryThe value of eCOA in the era of digitally derived measures — EClinCloud InsightsInsight6 min readThe value of eCOA in the era of digitally derived measuresAs clinical research explores digitally derived measures, eCOA can connect patient experience with other digital measurements through fit-for-purpose assessments and sound data quality management.